The search for promising new targets in cancer immunotherapy is one of the top priorities in biopharma and Claudin18.2’s potential in gastric cancer has become one of the hottest emerging areas.
That promise has been highlighted by a new deal between AstraZeneca with Chinese biotech KYM Biosciences to develop CMG901,...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
